c-Rel inhibitor (IC50
= 3 μ
M). Inhibits IL-2 expression in activated T-cells in vitro
. Reduces severity of graft-versus-host disease following hematopoietic stem cell transplant (HSCT) and inhibits growth of human B-cell lymphoma xenografts in mice. Inhibits the oxidative stress response in lymphoma cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Characterization of a c-Rel inhibitor that mediates anticancer properties in hematologic malignancies by blocking NF-κB-controlled oxidative stress responses.
Shono et al.
Cancer Res., 2016;76:377